Immunome (IMNM) Payables (2019 - 2026)

Immunome has reported Payables for 8 years, with the latest figure at $5.5 million in Q1 2026.

• For the quarter ending Q1 2026, Payables fell 39.36% year-over-year to $5.5 million; the trailing twelve-month figure through Mar 2026 stood at $5.5 million (down 39.36% YoY), and the FY2025 full-year result was $3.3 million, down 76.47% from the prior year.
• Payables for Q1 2026 stood at $5.5 million, up from $3.3 million in the prior quarter.
• The five-year high for Payables was $14.2 million in Q4 2024, with the low at $2.4 million in Q4 2022.
• Historically, Payables has averaged $5.2 million across 5 years, with a median of $3.9 million in 2022.
• Annual changes were most pronounced in 2024 — Payables jumped 328.54% — and 2025, when it tumbled 76.47%.
• Immunome's Payables stood at $2.4 million in 2022, then surged by 37.96% to $3.3 million in 2023, then jumped by 328.54% to $14.2 million in 2024, then plunged by 76.47% to $3.3 million in 2025, then soared by 65.74% to $5.5 million in 2026.
• The last three Payables figures came in at $5.5 million (Q1 2026), $3.3 million (Q4 2025), and $6.1 million (Q3 2025), per Business Quant data.